Litcius/Paper detail

Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer

Tanya Gupta, Shaveta Vinayak, Melinda L. Telli

2022Breast Cancer Research and Treatment21 citationsDOI

Topics & Concepts

PARP inhibitorMedicineBreast cancerTriple-negative breast cancerCancer researchImmune checkpointOncologyMetastatic breast cancerInternal medicineCancerImmunotherapyPoly ADP ribose polymeraseBiologyPolymeraseGeneBiochemistryPARP inhibition in cancer therapyCancer Immunotherapy and BiomarkersCAR-T cell therapy research
Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer | Litcius